NCT00064233View on ClinicalTrials.gov

BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate

PHASE1CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions

Leukemia

Interventions

DRUG

dasatinib

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER